Quantification of Acamprosate in human plasma by LC-ESI-MS/MS with solid phase extraction: Application to a bioequivalence study

Determination of acamprosate in human plasma by UPLC–MS/MS: Application to therapeutic drug monitoring

“…Very few studies have been carried out to determine acamprosate in human plasma (Chabenat et al, 1987; Ghosh et al, 2011, 2012; Girault et al, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies.…”

“…Very few studies have been carried out to determine acamprosate in human plasma (Chabenat et al, 1987; Ghosh et al, 2011, 2012; Girault et al, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies. Some of these studies need complex sample preparation procedures such as derivatization, solid‐phase extraction and evaporation with a nitrogen stream (Chabenat et al, 1987; Girault et al, 1990; Kanala et al, 2013; Luo et al, 2015; Xu et al, 2009), while others use basic protein precipitation (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Rhee et al, 2008).…”

“…Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies. Some of these studies need complex sample preparation procedures such as derivatization, solid‐phase extraction and evaporation with a nitrogen stream (Chabenat et al, 1987; Girault et al, 1990; Kanala et al, 2013; Luo et al, 2015; Xu et al, 2009), while others use basic protein precipitation (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Rhee et al, 2008). Also, some of the studies presented in the literature include a calibration range suitable for therapeutic drug monitoring (Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009).…”

“…In this study, a rapid UPLC–MS/MS method was successfully developed for the determination of acamprosate in the human plasma for therapeutic drug monitoring. The sample preparation procedure in some studies (Chabenat et al, 1987; Girault et al, 1990; Kanala et al, 2013; Luo et al, 2015; Xu et al, 2009) is simple and has a short analysis time (Chabenat et al, 1987; Girault et al, 1990; Hammarberg et al, 2010; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009).…”

“…In the literature, there are very few analytical methods for the determination of acamprosate in human plasma (Chabenat, Ladure, Blanc‐Continsouza, Boismare, & Boucly, 1987; Ghosh, Jha, Shinde, & Chakraborty, 2011; Girault, Gobin, & Fourtillan, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). All of these methods were developed for the pharmacokinetics studies.…”